Advanced Cardiovascular Systems, Inc.

Abbott Cardiovascular Systems, Inc.

Leland Stanford Junior University

Cardiac Pacemakers, Inc.

Tautona Group LP

Evgenia Mandrusov

Syed F A Hossainy

Daryush Mirzaee

Vinayak Bhat

Judy A Guruwaiya

Paul M Consigny

Stephen D Pacetti

Eugene T Michal

Deborra Sanders Millare

Keith Edward Fong

Charles David Claude

Murthy V Simhambhatla

Syed F Hossainy

Srinivasan Sridharan

Ni Ding

Syed Faiyaz Ahmed Hossainy

Marshall L Sherman

Jeffrey A Steward

Gerald G Fuller

Deborra Sanders-Millare

C Travis Rappleye

Dary Mirzaee

Syed Faiyez Ahmed Hossainy

Albert K Chin

Rodney W Salo

William Earl Webler, Jr

Geoffrey C Gurtner

Jayakumar Rajadas

Michael T Longaker

Jessica G Chiu

Yan Shen

Gordon Saul

Wouter Erik Roorda

Jeong Soo Lee

John Joseph Stankus

Shubhayu Basu

Yung-Ming Chen

Florian Ludwig

Jinping Wan

Robert D Ainsworth

Deborah L Kilpatrick

Richard T Thornton

Gene Michal

Ashok A Shah

Florian Niklas Ludwig

Gabriel Asongwe

Christopher J Buchko

Ken Bueche

Joseph J Sciacca

Liangxuan Zhang

Mary B Michaels

Hong Ma

Nadine Ding

John Eric Henckel

Fidel Albert Urrabazo

Daniel Wiegand

Eugene Michel

Robert D Alnsworth

Coatings for implantable devices or endoluminal prosthesis, such as stents, are provided, including a method of forming the coatings. The coatings can be used for the delivery of an active ingredient or a combination of active ingredients.

Primer coatings for stents with oxide, anionic, or hydroxyl surface moieties

Numerous embodiments of a system and method for treating cardiac tissue are described. In one embodiment, bone marrow cells are extracted from a patient. The cells are then processed to isolate mononuclear cells, which can then be delivered back near the cardiac tissue of the patient.

Integrated system for on-site mononuclear cell acquisition, processing and delivery

Coatings for implantable devices having a chromium oxide layer and a method of forming the same

Methods, devices, kits and compositions to treat a myocardial infarction. In one embodiment, the method includes the prevention of remodeling of the infarct zone of the ventricle. In other embodiments, the method includes the introduction of structurally reinforcing agents. In other embodiments, agents are introduced into a ventricle to increase compliance of the ventricle. In an alternative embodiment, the prevention of remodeling includes the prevention of thinning of the ventricular infarct zone. In another embodiment, the prevention of remodeling and thinning of the infarct zone involves the cross-linking of collagen and prevention of collagen slipping. In other embodiments, the structurally reinforcing agent may be accompanied by other therapeutic agents. These agents may include but are not limited to pro-fibroblastic and angiogenic agents.

Methods and compositions to treat myocardial conditions

Engraftment of therapeutic cells and agents to a target site in an organism is enhanced by mechanical, chemical and biological methods and systems.

Intracoronary device and method of use thereof

Disclosed are compositions with sustained-release carriers associated with at least two different types of growth factors and methods of fabrication and treatments thereof. In some embodiments, simultaneous release of the growth factors may be preferred while in other embodiments, sequential release of the growth factors may be preferred. Application of at least two growth factors to an injury site, e.g., compromised cardiac tissue caused by, for example, myocardial infarction or ischemic heart failure, may better mimic and induce the complex growth factor signaling pathways necessary to improve cardiac function. When applied to a patient after a myocardial infarction or ischemic heart failure, multiple growth factors within a sustained-release carrier platform or platforms may cause a synergistic effect on injected cells intending to alleviate left ventricle remodeling. Methods of treatment include percutaneous, sub-xiphoid, and open chest methods using catheters and/or syringes.

Multiple growth factor compositions, methods of fabrication, and methods of treatment

Primer coatings for implantable devices or endoluminal prosthesis, such as stents, are provided, including a method of forming the coatings. The primer coatings can include a material with a high content of hydrogen bonding groups, such as some types of epoxy polymers and melamine formaldehydes. Coatings subsequently disposed over the primer coating can be used for the delivery of an active ingredient or a combination of active ingredients.

Primer layer coatings of a material with a high content of hydrogen bonding groups for implantable devices and a method of forming the same

Disclosed are compositions, methods, and kits for joining together non-conjoined lumens in a patient's body including vascular lumens. More particularly, in various aspects, this invention provides compositions, methods, and kits for joining such non-conjoined lumens, including small lumens typically requiring microsurgical technique.

Compositions and methods for joining non-conjoined lumens

A method including positioning a delivery device at a location in a blood vessel; advancing the delivery device a distance into a wall of the blood vessel to a treatment site beyond an external elastic lamina of the blood vessel; and after advancing the delivery device, introducing a treatment agent including a cellular component through the delivery device. A composition including a treatment agent comprising a cellular component associated with a matrix material, wherein the composition is suitable for percutaneous delivery. Also an apparatus suitable for delivering a treatment agent. Also, a kit including a treatment agent.

Method for intravascular delivery of a treatment agent beyond a blood vessel wall

A method including positioning a catheter at a location in a blood vessel; imaging a thickness of a portion of a wall of the blood vessel at the location; identifying a treatment site; advancing a needle a distance into the wall of the blood vessel to the treatment site; and introducing a treatment agent through the needle to the treatment site. A composition including an inflammation-inducing agent and a carrier in the form of microspheres having a particle size suitable for transvascular delivery. A composition including a therapeutic angiogenesis promoter in a carrier and an opsonin-inhibitor coupled to the carrier. An apparatus for delivery of a therapeutic angiogenesis promoter.

Agents that stimulate therapeutic angiogenesis and techniques and devices that enable their delivery

Implantable devices comprising cyanoacrylate primer coatings

Methods, devices, kits and compositions to treat a myocardial infarction. In one embodiment, the method includes the prevention of remodeling of the infarct zone of the ventricle. In other embodiments, the method includes the introduction of structurally reinforcing agents. In other embodiments, agents are introduced into a ventricle to increase compliance of the ventricle. In an alternative embodiment, the prevention of remodeling includes the prevention of thinning of the ventricular infarct zone. In another embodiment, the prevention of remodeling and thinning of the infarct zone involves the cross-linking of collagen and prevention of collagen slipping. In other embodiments, the structurally reinforcing agent may be accompanied by other therapeutic agents. These agents may include, but are not, limited to pro-fibroblastic and angiogenic agents.

Primer coating of inorganic material for implantable devices

Isocyanate coatings for implantable devices and a method of forming the same

Growing community of inventors

Campbell, CA, United States of America

Evgenia Mandrusov